Table 2. Univariate analysis of use and duration of use of chemotherapy for high-risk patients.
| High-risk | Duration of chemotherapy for high-risk patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| No chemotherapy | Chemotherapy | ≤3 months | 4-8 months | |||||||
|
| ||||||||||
| N | (%) | N | (%) | P-value | N | (%) | N | (%) | P-value | |
| 212 | (28.1) | 542 | (71.9) | 215 | (44.2) | 271 | (55.8) | |||
| Age (years) | <0.001 | 0.45 | ||||||||
| 65-69 | 32 | (15.1) | 172 | (31.7) | 64 | (29.8) | 94 | (34.7) | ||
| 70-74 | 39 | (18.4) | 187 | (34.5) | 79 | (36.7) | 84 | (31.0) | ||
| 75-79 | 45 | (21.2) | 105 | (19.4) | 40 | (18.6) | 57 | (21.0) | ||
| ≥80 | 96 | (45.3) | 78 | (14.4) | 32 | (14.9) | 36 | (13.3) | ||
| Race | 0.10 | 0.24 | ||||||||
| White | 184 | (86.8) | 498 | (91.9) | 200 | (93.0) | 246 | (90.8) | ||
| Black | 11 | (5.2) | 19 | (3.5) | * | * | * | * | ||
| Other/unknown | 17 | (8.0) | 25 | (4.6) | * | * | * | * | ||
| Year of diagnosis | 0.68 | 0.20 | ||||||||
| 1992-1996 | 43 | (20.3) | 101 | (18.6) | 32 | (14.9) | 60 | (22.1) | ||
| 1997-2001 | 54 | (25.5) | 126 | (23.3) | 54 | (25.1) | 59 | (21.8) | ||
| 2002-2005 | 57 | (26.9) | 143 | (26.4) | 62 | (28.8) | 67 | (24.7) | ||
| 2006-2009 | 58 | (27.4) | 172 | (31.7) | 67 | (31.2) | 85 | (31.4) | ||
| Marital status | <0.001 | 0.17 | ||||||||
| Married | 78 | (36.8) | 277 | (51.1) | 119 | (55.4) | 133 | (49.1) | ||
| Unmarried/unknown | 134 | (63.2) | 265 | (48.9) | 96 | (44.7) | 138 | (50.9) | ||
| Area of residence | 0.15 | 0.98 | ||||||||
| Metropolitan | 184 | (86.8) | 490 | (90.4) | 195 | (90.7) | 246 | (90.8) | ||
| Non-metropolitan | 28 | (13.2) | 52 | (9.6) | 20 | (9.3) | 25 | (9.2) | ||
| SEER registry | 0.41 | 0.35 | ||||||||
| Eastern | 43 | (20.3) | 130 | (24.0) | 45 | (20.9) | 72 | (26.6) | ||
| Midwest | 90 | (42.5) | 234 | (43.2) | 97 | (45.1) | 114 | (42.1) | ||
| West | 79 | (37.3) | 178 | (32.8) | 73 | (34.0) | 85 | (31.4) | ||
| Socioeconomic status | 0.002 | 0.02 | ||||||||
| Lowest (first) quintile | 34 | (16.0) | 55 | (10.2) | 15 | (7.0) | 31 | (11.4) | ||
| Second quintile | 47 | (22.2) | 89 | (16.4) | 35 | (16.3) | 44 | (16.2) | ||
| Third quintile | 51 | (24.1) | 126 | (23.3) | 62 | (28.8) | 49 | (18.1) | ||
| Fourth quintile | 45 | (21.2) | 115 | (21.2) | 38 | (17.7) | 68 | (25.1) | ||
| Highest (fifth) | 35 | (16.5) | 157 | (29.0) | 65 | (30.2) | 79 | (29.2) | ||
| quintile/unknown | ||||||||||
| Comorbidity score | 0.001 | 0.14 | ||||||||
| 0 | 127 | (59.9) | 377 | (69.6) | 142 | (66.1) | 193 | (71.2) | ||
| 1 | 46 | (21.7) | 119 | (22.0) | 57 | (26.5) | 52 | (19.2) | ||
| ≥2 | 39 | (18.4) | 46 | (8.5) | 16 | (7.4) | 26 | (9.6) | ||
| Lymphadenectomy | <0.001 | 0.001 | ||||||||
| No/unknown | 135 | (63.7) | 246 | (45.4) | 79 | (36.7) | 139 | (51.3) | ||
| Yes | 77 | (36.3) | 296 | (54.6) | 136 | (63.3) | 132 | (48.7) | ||
| Omentectomy | <0.001 | 0.60 | ||||||||
| No | 90 | (42.5) | 150 | (27.7) | 55 | (25.6) | 75 | (27.7) | ||
| Yes | 122 | (57.6) | 392 | (72.3) | 160 | (74.4) | 196 | (72.3) | ||
| Histology | 0.20 | 0.75 | ||||||||
| Serous | 61 | (28.8) | 196 | (36.2) | 78 | (36.3) | 101 | (37.3) | ||
| Mucinous | 24 | (11.3) | 60 | (11.1) | 21 | (9.8) | 32 | (11.8) | ||
| Endometrioid | 45 | (21.2) | 119 | (22.0) | 44 | (20.5) | 61 | (22.5) | ||
| Clear cell | 54 | (25.5) | 118 | (21.8) | 49 | (22.8) | 55 | (20.3) | ||
| Other | 28 | (13.2) | 49 | (9.0) | 23 | (10.7) | 22 | (8.1) | ||
| Grade | 0.13 | 0.83 | ||||||||
| 1 | 22 | (10.4) | 39 | (7.2) | 14 | (6.5) | 21 | (7.8) | ||
| 2 | 29 | (13.7) | 102 | (18.8) | 37 | (17.2) | 52 | (19.2) | ||
| 3 | 116 | (54.7) | 308 | (56.8) | 129 | (60.0) | 152 | (56.1) | ||
| Unknown | 45 | (21.2) | 93 | (17.2) | 35 | (16.3) | 46 | (17.0) | ||
| Stage | <0.001 | 0.003 | ||||||||
| IA | 100 | (47.2) | 164 | (30.3) | 84 | (39.1) | 65 | (24.0) | ||
| IB | * | * | 29 | (5.4) | * | * | * | * | ||
| IC | 98 | (46.2) | 336 | (62.0) | 119 | (55.4) | 181 | (66.8) | ||
| INOS | * | * | 13 | (2.4) | * | * | * | * | ||
*
Cell ≤10.